Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity

Oncology

Volumn 62, Issue 2, 2002, Pages 180-184

  Saga, Yasushi ^a   Suzuki, Mitsuaki ^a   Machida, Shizuo ^a   Ohwada, Michitaka ^a   Sato, Ikuo ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; Clear cell adenocarcinoma; Gemcitabine; Irinotecan; Ovarian cancer; p53; Paclitaxel; PTEN; Radiation; TAYA

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; GEMCITABINE; PACLITAXEL;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER INHIBITION; CASE REPORT; CLEAR CELL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; CHROMOSOMES; COLORIMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; KINETICS; MUTATION; OVARIAN NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0036201642     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048265     Document Type: Article

References (19)

1. Ovarian clear cell adenocarcinoma
2. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
3. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy
4. Clinical characteristics of clear cell carcinoma of the ovary
5. Clear cell carcinoma of the ovary: Poor prognosis compared to serous carcinoma
6. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy
7. Recurrent ovarian clear cell carcinoma: Complete remission after radiation in combination with hyperthermia; a case study and in vitro study
8. A rapid banding technique for human chromosomes
9. Establishment and characterization of a new cell line (SKS) from neuroendocrine small cell carcinoma of the uterine cervix and its chemosensitivity
10. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene
11. Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer
12. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
13. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies
14. p53 mutations and expression in ovarian cancers: Correlation with overall survival
15. Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer
16. p53 mutation is infrequent in clear cell carcinoma of the ovary
17. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
18. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
19. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors